We debut our first ever "Ask a Psychotherapist" segment where we take questions submitted by our listeners and have Kelli Foulkrod, a transpersonal psychotherapist, answer them.
Similar Posts
Interview With Nick Levich
Psychedelic Passage’s Co-Founder and Facilitator, Nick Levich, talks about the function, purpose and importance of a trip sitter during a psychedelic experience.
Numinus Acquires Novamind: What Does This Mean for the Psychedelic Industry? | NUMI, NM
Numinus Acquiring Novamind in First Major Psychedelics Merger
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Not only will this be your chance to meet me, but also the legendary Paul Stamets!
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Back to Numinus
This acquisition will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.
Psychedelic stock investors woke up to some major news today: Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) announced that they are acquiring Novamind Inc. (CSE: NM) (OTCQB: NVMDF).
The acquisition will be done in stock, and shareholders of Novamind will receive 0.84 of a common share of Numinus per Novamind share held, implying an offer price of $0.44 per Novamind share. This means Numinus is offering a premium of 51% to Novamind shareholders, based on the 20-day volume-weighted average price of their stock. When the transaction is completed, Novamind shareholders will own around 18% of Numinus.
If you currently hold Novamind stock, you do not need to do anything. When the transaction is finalized, each Novamind share you own will automatically be transformed into 0.84 of a Numinus share.
#Numinus #NovaMind #psychedelicStocks
Find Your Inner Healing with Psychedelic Therapy | ATMA CEO Interview
In today’s episode of PSYCBiz, James, the Psychedelic Investor, sits down with David Harder, Co-CEO of ATMA.
ATMA is a company that is primarily focused on training therapists on how to conduct psychedelic therapy.
The company also has plans to launch psilocybin clinical trials, treat depression patients in Canada under the SAP program, and work with Oregon in their legalization of psilocybin therapy.
This interview took place at the Catalyst Summit, a psychedelic conference that David Harder helped organize. This conference saw big names like Paul Stamets attend.
In the conversation, David and James get philosophical and discuss the nature of psychedelics and consciousness. Topics such as the right to try are also discussed.
To learn more about ATMA, visit: https://www.atmajourney.com/
To learn more about Catalyst, visit: https://catalystpresents.ca/
#psychedelics #therapy #magicmushrooms
![This Week in Psychedelic Stocks [Big UPDATES ON MMEDF, CMPS, FTRPF, and ATAI]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-33-600x338.jpeg)
This Week in Psychedelic Stocks [Big UPDATES ON MMEDF, CMPS, FTRPF, and ATAI]
Hello Psychedelic Investors! In this new segment entitled “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF), Compass Pathways (CMPS), Atai Life Sciences, and Field Trip Health (FTRPF/ FTRP).
We will cover the latest developments in the field writ large,
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.
Time Stamps
0:00 – Intro
0:56 – California Legalizing Psychedelics?
2:09 – Texas Legalizing Psychedelics?
3:33 – STOP LICKING TOADS DUDE
4:05 – MindMed Stock Updates (MMED / MMEDF)
9:13 – Compass Pathways Stock Updates (CMPS)
13:25 – Atai Life Sciences Update
17:05 – Field Trip Health Stock Updates (FTRPF/ FTRP)
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
How to Microdose Magic Mushrooms in 5 EASY Steps For Beginners (Plus: Does Microdosing Really Work?)
In this episode, we’re covering what is microdosing and its purported benefits. You will learn how to microdose magic mushrooms. How to microdose psychedelics.
Microdosing is the practice of taking a small dose of a drug, in our case psilocybin, the main active ingredient in magic mushrooms. The dose is small enough that it won’t cause any perceptual changes, meaning you won’t have any hallucinations or even feel high.
This will allow you to continue to go to school, work, or get more comfortable in social settings.
According to thousands upon thousands of anecdotal stories over decades, microdosing psilocybin is purported to:
– Improve your creativity;
– Help you enter states of flow, also known as “being in the zone” or entering a mental state of total energized concentration;
– Help alleviate feelings of stress and anxiety;
– Improve focus and concentration;
– Improves relational awareness and;
– Speeds your reflexes.
We have to rely on anecdotal evidence unfortunately, because until recently, very little scientific study has been done on the subject of microdosing, though that is starting to change with many clinical studies underway.
Despite a lack of hard scientific data, the practice is sworn upon by many in high pace environments, such as Silicon Valley. A couple famous examples of microdosers include: Joe Rogan and Steve Jobs, though for the later it was more LSD microdosing.
Let me know in the comments if you want to see a video on LSD microdosing in the future.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MicrodosingMushrooms #Microdosing #MagicMushrooms
Removing Barriers of Accessibility to Psychedelics with Brett Waters
Brett also introduces the collaborative efforts of Reason for Hope’s team, which includes strategic minds from various fields, working together in drafting legislation, preparing legal briefings, educating legislators, and building advocacy coalitions. Currently, Reason for Hope focuses on establishing MDMA- and psilocybin-assisted therapy expanded access pilot programs for those unable to wait for FDA approval.